Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price levels.

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro ... stock's fair value lies ~17.4% above today's price. I initiate coverage with ...

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound ... and the new prices, $399 or $549 a month, are still prohibitive for ...

This is the second time Zepbound’s sales have fallen short of market predictions since its launch late last year. Following this announcement, Eli Lilly’s stock price plummeted, experiencing ...